

# **Lung & Kidney: Best First Cases to Develop Your Practice**

Alda Tam, MD

Professor, Interventional Radiology

MD Anderson Cancer Center

# Faculty Disclosures

Research Funding — Boston Scientific, Johnson & Johnson; Consulting — Cello Therapeutics, Boston Scientific, AstraZeneca, Endocare

Brand names are included in this presentation for participant clarification purposes only. No product promotion should be inferred.

# Lung

- **Metastases >> NSCLC**
  - Identify oncologists & surgeons (surg onc and thoracic surg) who treat the most colon cancer and sarcoma cases
  - Parenchymal sparing advantage
    - Medically high risk for surgery; prior thoracotomy, prior XRT
  - Image-guided thermal ablation has been successfully accomplished in “high risk,” objectively defined with a single major and/or two or more minor criteria. Major criteria included an FEV1 or DLCO  $\leq 50\%$ , and minor criteria, a less depressed FEV1 or DLCO between 51-60%, advanced age  $\geq 75$  years, pulmonary hypertension, LVEF  $\leq 40\%$ , resting or exercise PaO<sub>2</sub>  $< 55$  mmHg, and pCO<sub>2</sub>  $> 45$  mmHg

# Lung

**TABLE 1.** Comparing Ablative Technologies

Parameter(s)	Radiofrequency	Microwave	Cryoablation
Set up	++	+++ (quickest)	+
Duration of ablation	++	+++ (shortest)	+
≤ 3 cm	+++	+++	+++
> 3 cm	+	+++	++
≤ 1.5 cm pleura	+ (pain)	+ (pain, air leak)	+++
Emphysema	++	+++	+
Chest wall	+	++	+++
Mediastinum	+	+	++
Thermal sinks	+	+++ (least)	++
Preservation of collagen	+	+	+++
Coagulopathies	+++	+++	+


## Tumor Factors

- Size: < 3 cm
- Number: 4/lung
- Location: Peripheral
- No extrapulmonary mets
- Biology: RCC, CRC, sarcoma


Abtin et al. *J Thorac Imaging*. 2019;34:266-77


## Defining New Metrics in Microwave Ablation of Pulmonary Tumors: Ablation Work and Ablation Resistance Score

Ramsey A. Al-Hakim, MD, Fereidoun G. Abtin, MD, Scott J. Genshaft, MD, Erin Kutay, MD, MPH, and Robert D. Suh, MD



**Figure 1.** Schematic demonstrating different ablation resistance score groups: low score (ablation resistance score = 2–3), medium score (ablation resistance score = 4), and high score (ablation resistance score = 5–6). Dashed lines indicate divisions between pulmonary regions, and solid lines indicate divisions between pulmonary lobes. Dot-dashed line represents division between left upper lobe and lingula. *J Vasc Interv Radiol* 2016; 27:1380–1386









61-year-old woman w/rectal cancer & synchronous lung metastasis dx'ed 2013. Treated with transanal excision & neoadjuvant radiation along with concurrent capecitabine. In 2014: APR w/partial posterior vaginectomy and VRAM flap reconstruction followed by adjuvant FOLFOX + bevacizumab and bilateral thoracotomies w/multiple wedge resections.



75-year-old woman with uterine leiomyosarcoma treated with TAH/BSO in 1999. Poor tolerance to doxorubicin/isoferosamide, completed 2001. Surgical wedge resections for bilateral pulmonary mets in 2001, 2003, 2011. Patient on surveillance since 2015 without evidence of new disease or recurrence.



# Kidney

- Identify urologists, oncologists, and orthopedic surgeons treating the most RCC in your institution
- Good support for IR interventions in the NCCN guidelines for stage T1a and recurrent/metastatic disease
- RCC represents a disease state with multiple opportunities for IR to provide added value to patient care

# Kidney

- Ablation for primary stage T1a RCC
- Ablation for recurrent RCC in kidney
- Embolization for large, hypervascular primary RCC w/wo venous invasion prior to resection
- Embolization for symptomatic primary RCC
- Ablation of soft tissue/bone/liver/lung metastases from RCC

# Kidney




- Ablation for primary stage T1a RCC
- Ablation for recurrent RCC in kidney

Tumor size:

- < 4 cm ideal
- > 4 cm may require additional interventions

Tumor location:



- Non-central tumors have better response rates
- Posterior/posterolateral tumors are more accessible



# Kidney

- Embolization for large, hypervascular primary RCC w/wo venous invasion prior to resection
- Embolization for symptomatic primary RCC
- **MDACC 1999 – 2003:**
  - 30 patients underwent preoperative embolization
  - 25 patients (83%) with IVC tumor thrombus
  - Mean tumor size 11.5 cm


Findings During Surgery	No. of Cases	Avg. Tumor Size	Avg. EBL(L)	Median Surgery Delay
Significant Edema/Inflammation	12	9.5	3.2	2.5
No significant Edema/Inflammation	17	13.3	1.6	1.0
			$P = .02$	$P = .03$



# Kidney

- Ablation of soft tissue/bone/liver/lung metastases from RCC

75-year-old man with metastatic RCC involving the right superior acetabulum



# Conclusions

- Multidisciplinary practice – get to know the other players
- Use well-selected cases to develop familiarity with devices
  - Knowing how a device performs will allow you to take on more challenging cases while preserving safety margin
- Lung ablation – build the practice on metastatic disease
- Kidney – variety of clinical scenarios and multiple points within disease course to integrate IR interventions into the institutional practice